Archive | October, 2017

Adverse Sexual Side Effects linked to popular BPH drug

Dutasteride is a common medication used for treatment of Benign Prostatic Hyperplasia (BPH).

The findings of a new observational study supports a link between long-term dutasteride (5 alpha reductase inhibitor or 5-ARI) use and adverse sexual side effects, including worsening ED and reduced testosterone levels.

According to the author Abdulmaged M. Traish, MBA, PhD, of Boston University School of Medicine told Renal & Urology News. “The increase in blood glucose and A1C may predispose men to diabetes and the increase in lipids may predispose them to NAFLD [non-alcoholic fatty liver disease]. Most importantly, this agent worsens sexual function and reduces quality of life.”

Based on collected data, Dr. Traish and his colleagues found that dutasteride significantly improved LUTS over 36 to 42 months, according to results published in Hormones Molecular Biology and Clinical Investigations. It reduced prostate volume, International Prostate Symptom Score, and PSA. However, its use was also associated with increased blood glucose, hemoglobin A1c, triglycerides, and low-density lipoprotein levels over the long term. In addition, dutasteride appeared to increase liver transaminase activity and Aging Male Symptom score, which indicates inflammation and reduced quality of life.

Posted in Prostate HealthComments Off

Nondiabetic CKD Patients May Not Really Benefit From Intensive Blood Pressure Control

According to a new study published online in the Journal of Internal Medicine, Intensive blood pressure (BP) control in nondiabetic patients with moderate-to-advanced chronic kidney disease (CKD) may not lower their cardiovascular risks and could increase their risk of acute kidney injury (AKI).

Yoshitsugu Obi, MD, of the University of California Irvine, and colleagues found that intensive BP control did not reduce the risk of fatal and nonfatal cardiovascular events among 891 patients with an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m2.  His findings came from a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial) which consisted of 445 patients who received standard BP control and 446 who received intensive BP control.

AKI developed in 62 patients (13.9%) in the intensive control arm compared with 38 (8.5%) in the standard control arm. Intensive BP control was associated with a significant 73% increased risk of AKI.

Based on the current findings, Dr Obi and colleagues concluded that eGFR significantly modifies the risk-benefit profile of intensive BP control, which may provide little or no benefit and may be harmful to patients with an eGFR below 45 mL/min/1.73 m2.

Posted in Kidney HealthComments Off